Last €6.90 EUR
Change Today +0.077 / 1.13%
Volume 0.0
EP3 On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:01 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

orasure technologies inc (EP3) Snapshot

Open
€6.84
Previous Close
€6.83
Day High
€6.91
Day Low
€6.82
52 Week High
11/11/14 - €7.39
52 Week Low
02/5/14 - €3.99
Market Cap
386.9M
Average Volume 10 Days
10.0
EPS TTM
--
Shares Outstanding
56.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORASURE TECHNOLOGIES INC (EP3)

orasure technologies inc (EP3) Related Businessweek News

No Related Businessweek News Found

orasure technologies inc (EP3) Details

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies. It also offers other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The company’s principal products comprise OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene DISCOVER, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT L2P, Intercept, MICRO-PLATE DOA Assays, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, it manufactures and sell oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, the company offers medical devices used for the removal of benign skin lesions by cryosurgery or freezing; certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and the FDA 510(k) cleared Q.E.D. rapid point-of-care saliva alcohol test. OraSure Technologies, Inc. sells its products to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities in the United States and internationally. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.

293 Employees
Last Reported Date: 03/14/14
Founded in 1979

orasure technologies inc (EP3) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $563.4K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $442.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $319.7K
Executive Vice President of Marketing and Sal...
Total Annual Compensation: $362.0K
Compensation as of Fiscal Year 2013.

orasure technologies inc (EP3) Key Developments

Gerald Ostrov Resigns as Board of Director of OraSure Technologies, Inc., Effective November 11, 2014

OraSure Technologies, Inc. announced that Gerald Ostrov has resigned and retired from the Company's Board of Directors, effective November 11, 2014.

OraSure Technologies, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 09:00 AM

OraSure Technologies, Inc. Presents at Canaccord Genuity 2014 Medical Technologies & Diagnostics Forum, Nov-20-2014 09:00 AM. Venue: The Westin Grand Central, New York, New York, United States. Speakers: Douglas A. Michels, Chief Executive Officer, President and Director.

OraSure Technologies Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014

OraSure Technologies Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net revenues of $27,845,000 compared to $24,671,000 a year ago, increase by 13%. Operating income was $882,000 compared to operating loss of $2,060,000 a year ago. Income before income taxes was $1,150,000 compared to loss before income taxes of $2,019,000 a year ago. Net income was $1,140,000 or $0.02 per basic and diluted share compared to net loss of $1,892,000 or $0.03 per basic and diluted share a year ago. Consolidated gross margin was 67% For the nine months, the company reported revenues of $77,783,000 compared to $70,172,000 a year ago, increase by 11%. Operating loss was $2,239,000 compared to $18,225,000 a year ago. Loss before income taxes was $1,995,000 compared to $18,189,000 a year ago. Net loss was $1,962,000 or $0.04 per basic and diluted share compared to $17,403,000 or $0.31 per basic and diluted share a year ago. Capital expenditures were $2,353,000 compared to $1,696,000 a year ago. Cash provided by operating activities was $8,384,000 compared to cash used in operating activities of $3,142,000 a year ago. Consolidated gross margin was 63% For the fourth quarter, the company expects consolidated net revenues to range from $28.0 to $28.5 million and is projecting a consolidated net loss of approximately $0.04 to $0.05 per share for the fourth quarter of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EP3:GR €6.90 EUR +0.077

EP3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Meridian Bioscience Inc $15.94 USD -0.15
Momenta Pharmaceuticals Inc $11.51 USD +0.19
Pernix Therapeutics Holdings Inc $10.36 USD -0.23
Quidel Corp $27.83 USD +0.35
Trinity Biotech PLC $16.87 USD -0.17
View Industry Companies
 

Industry Analysis

EP3

Industry Average

Valuation EP3 Industry Range
Price/Earnings 100.0x
Price/Sales 4.6x
Price/Book 3.1x
Price/Cash Flow 116.2x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORASURE TECHNOLOGIES INC, please visit www.orasure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.